Charles Schwab
BOLD

Charles Schwab’s Audentes Therapeutics, Inc BOLD Stock Holding History

Charles Schwab’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-280,904
Closed -$16.8M – 3274
2019
Q4 		$16.8M Buy
280,904
+7,274
+3% +$273K 0.01% 1336
2019
Q3 		$7.69M Buy
273,630
+48,508
+22% +$1.66M ﹤0.01% 1757
2019
Q2 		$8.52M Buy
225,122
+21,158
+10% +$813K 0.01% 1701
2019
Q1 		$7.96M Buy
203,964
+8,271
+4% +$237K 0.01% 1730
2018
Q4 		$4.17M Buy
195,693
+24,960
+15% +$644K ﹤0.01% 1998
2018
Q3 		$6.76M Buy
170,733
+103,073
+152% +$3.84M ﹤0.01% 1878
2018
Q2 		$2.59M Buy
67,660
+22,063
+48% +$817K ﹤0.01% 2295
2018
Q1 		$1.37M Buy
45,597
+11,000
+32% +$372K ﹤0.01% 2432
2017
Q4 		$1.08M Buy
34,597
+8,997
+35% +$247K ﹤0.01% 2488
2017
Q3 		$718K Hold
25,600
– – ﹤0.01% 2613
2017
Q2 		$490K Buy
25,600
+14,900
+139% +$238K ﹤0.01% 2698
2017
Q1 		$183K Hold
10,700
– – ﹤0.01% 2943
2016
Q4 		$196K Buy
+10,700
New +$185K ﹤0.01% 2968

Charles Schwab's BOLD Position: Q1 2020 in Review

Charles Schwab sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 280,904 shares — an estimated $16.8M sold.

Charles Schwab first reported a position in BOLD in Q4 2016 and held it in 13 quarters. The position peaked at $16.8M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • Charles Schwab reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Charles Schwab sold 280,904 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $16.8M.
  • Charles Schwab first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 13 quarters.
  • Charles Schwab's Audentes Therapeutics, Inc position peaked at $16.8M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Charles Schwab's 13F filing for Q1 2020, filed 15 May 2020.